Compellis Pharmaceuticals Awarded Patent For Its Therapeutic Platform For Treating Obesity

December 7, 2006 – 10:48 am | posted in Obesity / Weight Loss

Compellis Pharmaceuticals, a biopharmaceutical company developing novel mechanism-based therapeutics for the treatment of obesity, announced today that it has been issued a patent (7,138,107) by the U.S. Patent and Trademark Office (USPTO) for its invention entitled “Inhibition of olfactory neurosensory function to treat obesity and related disorders.” The patent protects key aspects of Compellis’ novel obesity therapeutic strategy. Compellis has successfully demonstrated its therapeutic effect on weight gain in pre-clinical animal models and the results are published in Pharmacology, Biochemistry and Behavior.

??”This patent represents a significant milestone for Compellis as it marks the first issued patent protecting our therapeutic platform for treating obesity,” said Chris Adams, president and chief executive officer of Compellis Pharmaceuticals. “The issuance of this patent follows the completion of rigorous pre-clinical work for our first clinical product, CP404. We are very excited with the significant progress that has been made in demonstrating the ability of our therapeutic approach to produce significant weight loss effects in proven animal models. Compellis will begin human testing of CP404 in 2007.”

??The USPTO has recognized the unique aspects of the Compellis therapeutic approach and granted the initial patent in a series of patent applications covering the platform technology.

??CP404 is a calcium channel blocker used in a nasal formulation to block olfactory activity and reduce food intake. Compellis has tested a series of like compounds and believes the effect can be seen in the overall class of calcium channel blockers. The advantage of CP404 is that it is a small molecule that is well tolerated in humans and is readily manufactured. Based on its prior use in humans for certain other disorders Compellis believes it will be eliminating some of the drawbacks typically associated with unproven compounds. The result will be a focused clinical development process that may result in a faster time to market.

ShareThis

Also Read

  • OREXIGEN(TM) Therapeutics Announces Issuance Of Broad Patents Covering Composition Of Its Lead Anti-Obesity Compounds
  • Collegium Pharmaceutical Inc. Announces Notice Of Allowance For U.S. Patent For Its DETERx(TM) Abuse Deterrent Sustained Release Technology
  • Koronis Pharmaceuticals Receives Notice Of Allowance On Patent For Novel Therapeutic KP-1461 In Development For Treatment Of HIV
  • Takeda Wins Patent Infringement Litigation On Appeal Against ANDA Filers For Generic ACTOS®
  • EU Platform For Action On Diet, Physical Activity And Health
  • Joined Up Approach Needed To Combat Obesity? BMA Response To NICE Guidelines, UK
  • Positive Phase I Results Reported For DURECT’s Second Abuse-Resistant Opioid Pain Medicine
  • Celator(R) Pharmaceuticals Study Shows CPX-571 Maintains Synergistic Ratio Of Irinotecan And Cisplatin To Improve Anti-tumor Activity
  • Merrimack Pharmaceuticals Initiates Enrollment In A Phase 2 Study Of MM-093 In Patients With Rheumatoid Arthritis
  • Doubt Cast On Routine Screening To Pick Up Overweight And Obese Schoolchildren

    • You must be logged in to post a comment.